- Barrons.com
Cassava Sciences Shares Plunge on Indictment Against Former Advisor
A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits.
- Zacks
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
- InvestorPlace
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
Investing in the biotech sphere isn’t for the faint of heart, and you should steer clear of the biotech stocks to avoid. That’s because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals. Unsurprisingly, the SPDR S&P Biotech ETF had shed roughly 40% in value over the past three years, when the broader market gained 22%. Hence, investors pondering over biotech stocks to avoid them will always remain relevant. Moreover, they’re probably
